<DOC>
	<DOCNO>NCT02526030</DOCNO>
	<brief_summary>The selection antipsychotic early stage illness mainly determine clinical effectiveness . Second generation antipsychotic ( SGAs ) first line drug treatment individual suffer schizophrenia . It clear SGAs homogeneous group clinical effect profile side effect differ SGAs . Differences among antipsychotic term effectiveness turn topic increase research interest , although comparison different SGAs scarce . In first episode psychosis , SGAs show higher treatment effectiveness compare first generation antipsychotic ( FGAs ) ( finding primarily driven Haloperidol ) . Less evident seem notion SGAs might effective ( term treatment discontinuation ) others . Most medium-term randomized study show similar rate all-cause treatment discontinuation first episode patient treat different SGAs . It may conclude randomized control trail accomplish determine position frequently use SGAs clinical practice . Investigators undertake study major objective compare clinical effectiveness three widely utilized SGAs ( Aripiprazole , Ziprasidone Quetiapine ) acute treatment first-episode non-affective psychosis individual 3 year follow-up .</brief_summary>
	<brief_title>Comparative Study Aripiprazole , Quetiapine Ziprasidone Treatment First Episode Psychosis : 3-year Follow-up</brief_title>
	<detailed_description>Study set financial support : data present investigation obtain ongoing epidemiological three-year longitudinal intervention program first-episode psychosis ( PAFIP ) conduct outpatient clinic inpatient unit University Hospital Marqu√©s de Valdecilla , Spain . Conforming international standard research ethic , program approve local institutional review board . Patients meet inclusion criterion family provide write informed consent include PAFIP . The Mental Health Services Cantabria provide fund implement program . None pharmaceutical company supply financial support . Study design : severity scale Clinical Global Impression ( CGI ) scale , Brief Psychiatric Rating Scale ( BPRS ) , Scale Assessment Positive symptom ( SAPS ) Scale Assessment Negative symptom ( SANS ) use evaluate symptomatology . To assess general adverse event experience Scale Udvalg Kliniske Undersogelser ( UKU ) , Simpson-Angus Rating Scale ( SARS ) Barnes Akathisia Scale ( BAS ) use assess side effect . The adverse event evaluate use UKU Side effect rating scale . Those treatment-emergent adverse event occur rate least 10 % either treatment group consider . Treatment-emergent akathisia ( BAS ) extrapyramidal symptom ( SARS ) assess baseline-to-end change newly emergent categorical change . The trained psychiatrist ( BC-F ) complete clinical assessment .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Patients follow First Episode Psychosis Clinical Program ( PAFIP II ) October 2005 January 2011 . Meeting Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) criteria drug dependence Meeting DSMIV criterion mental retardation Having history neurological disease head injury .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>psychosis</keyword>
	<keyword>antipsychotic agent</keyword>
	<keyword>treatment</keyword>
	<keyword>effectiveness</keyword>
</DOC>